Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies.

Cell-free DNA DNA Methylation Epigenetic Biomarker Liquid Biopsy Lung Cancer Subtyping

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
19 Sep 2019
Historique:
received: 07 08 2019
revised: 15 09 2019
accepted: 17 09 2019
entrez: 25 9 2019
pubmed: 25 9 2019
medline: 25 9 2019
Statut: epublish

Résumé

Lung cancer (LCa) is the most frequently diagnosed and lethal cancer worldwide. Histopathological subtyping, which has important therapeutic and prognostic implications, requires material collection through invasive procedures, which might be insufficient to enable definitive diagnosis. Aberrant DNA methylation is an early event in carcinogenesis, detectable in circulating cell-free DNA (ccfDNA). Herein, we aimed to assess methylation of selected genes in ccfDNA from LCa patients and determine its accuracy for tumor subtyping. Methylation levels of In study group #2, Methylation level assessments in ccfDNA may provide a minimally invasive procedure for LCa subtyping, complementing standard diagnostic procedures.

Sections du résumé

BACKGROUND BACKGROUND
Lung cancer (LCa) is the most frequently diagnosed and lethal cancer worldwide. Histopathological subtyping, which has important therapeutic and prognostic implications, requires material collection through invasive procedures, which might be insufficient to enable definitive diagnosis. Aberrant DNA methylation is an early event in carcinogenesis, detectable in circulating cell-free DNA (ccfDNA). Herein, we aimed to assess methylation of selected genes in ccfDNA from LCa patients and determine its accuracy for tumor subtyping.
METHODS METHODS
Methylation levels of
RESULTS RESULTS
In study group #2,
CONCLUSIONS CONCLUSIONS
Methylation level assessments in ccfDNA may provide a minimally invasive procedure for LCa subtyping, complementing standard diagnostic procedures.

Identifiants

DOI: 10.3390/jcm8091500 PMID: 31546933 PMC: PMC6780554
pubmed: 31546933
pii: jcm8091500
doi: 10.3390/jcm8091500
pmc: PMC6780554
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Research Center of Portuguese Oncology Institute of Porto
ID : PI 74-CI-IPOP-19-2016

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Mol Cancer Ther. 2001 Nov;1(1):61-7
pubmed: 12467239
Epidemiology. 2005 Jan;16(1):73-81
pubmed: 15613948
J Thorac Oncol. 2011 Oct;6(10):1632-8
pubmed: 21694641
Cancer. 2007 Nov 1;110(9):2019-26
pubmed: 17876837
Epigenomics. 2015;7(6):1003-15
pubmed: 26479312
Cancers (Basel). 2018 Sep 26;10(10):null
pubmed: 30261643
J Clin Oncol. 2009 Apr 20;27(12):2030-7
pubmed: 19273703
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Clin Cancer Res. 2014 Apr 1;20(7):1856-64
pubmed: 24486589
J Clin Oncol. 2004 Nov 15;22(22):4575-83
pubmed: 15542809
Future Oncol. 2018 Mar;14(6):567-575
pubmed: 29417838
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Cold Spring Harb Perspect Biol. 2016 Sep 01;8(9):null
pubmed: 27194046
Radiol Clin North Am. 2012 Sep;50(5):863-76
pubmed: 22974775
J Thorac Oncol. 2015 Mar;10(3):446-53
pubmed: 25695220
J Mol Diagn. 2012 Sep;14(5):510-7
pubmed: 22749746
Front Oncol. 2014 Sep 22;4:253
pubmed: 25295226
J Natl Cancer Inst. 2000 Aug 16;92(16):1303-7
pubmed: 10944551
Genomics Proteomics Bioinformatics. 2017 Apr;15(2):59-72
pubmed: 28392479
Clin Cancer Res. 2017 Nov 15;23(22):7141-7152
pubmed: 28855354
J Natl Cancer Inst. 2001 May 2;93(9):691-9
pubmed: 11333291
Clin Cancer Res. 2011 Jul 1;17(13):4494-503
pubmed: 21610147
Clin Cancer Res. 2017 Apr 15;23(8):1998-2005
pubmed: 27729459
Expert Opin Pharmacother. 2010 Jun;11(8):1387-402
pubmed: 20446853
Lung Cancer. 2007 Oct;58(1):131-8
pubmed: 17606310
Clin Cancer Res. 2001 Jul;7(7):1998-2004
pubmed: 11448917
Curr Oncol. 2012 Feb;19(1):e16-27
pubmed: 22328844
Oncol Lett. 2018 May;15(5):7639-7648
pubmed: 29725463
J Pathol Transl Med. 2018 Sep;52(5):283-289
pubmed: 30235512
Lung Cancer. 2018 Sep;123:44-51
pubmed: 30089594
J Clin Med. 2018 Jun 29;7(7):null
pubmed: 29966246
Eur J Cancer. 2014 Jan;50(1):226-33
pubmed: 24100025
PLoS One. 2018 May 31;13(5):e0195716
pubmed: 29851970
Lung Cancer. 2007 May;56(2):289-94
pubmed: 17267069
Methods. 2001 Dec;25(4):456-62
pubmed: 11846615
Clin Chem Lab Med. 2011 Apr;49(4):699-704
pubmed: 21480815
Crit Rev Oncol Hematol. 2013 Dec;88(3):494-503
pubmed: 23921082
BMC Bioinformatics. 2006 Sep 07;7:407
pubmed: 16959042
Virchows Arch. 2013 Dec;463(6):749-54
pubmed: 24126803
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Ann Oncol. 2015 Sep;26(9):1883-9
pubmed: 26105600
Cancer Chemother Pharmacol. 2013 Aug;72(2):453-61
pubmed: 23811982
J Natl Cancer Inst. 2004 Jul 21;96(14):1105-7
pubmed: 15265973
J Clin Oncol. 2006 Sep 10;24(26):4262-9
pubmed: 16908936

Auteurs

Sandra P Nunes (SP)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. sandra22nunes@gmail.com.

Francisca Diniz (F)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. franciscadiniz93@gmail.com.

Catarina Moreira-Barbosa (C)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. catarina.moreira.barbosa@gmail.com.

Vera Constâncio (V)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. veraconstancio24@gmail.com.

Ana Victor Silva (AV)

Lung Cancer Clinic and Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. ana.v.silva@ipoporto.min-saude.pt.

Júlio Oliveira (J)

Lung Cancer Clinic and Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt.

Marta Soares (M)

Lung Cancer Clinic and Department of Medical Oncology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. martasoares@ipoporto.min-saude.pt.

Sofia Paulino (S)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. sofia.paulino@ipoporto.min-saude.pt.
Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. sofia.paulino@ipoporto.min-saude.pt.

Ana Luísa Cunha (AL)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. analuisa.cunha@ipoporto.min-saude.pt.
Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. analuisa.cunha@ipoporto.min-saude.pt.

Jéssica Rodrigues (J)

Department of Epidemiology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. jessica.rocha.rodrigues@ipoporto.min-saude.pt.

Luís Antunes (L)

Department of Epidemiology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. luis.antunes@ipoporto.min-saude.pt.

Rui Henrique (R)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. rmhenrique@icbas.up.pt.
Department of Pathology, Portuguese Oncology Institute of Porto, 4200-072 Porto, Portugal. rmhenrique@icbas.up.pt.
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. rmhenrique@icbas.up.pt.

Carmen Jerónimo (C)

Cancer Biology & Epigenetics Group - Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), 4200-072 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4050-313 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.

Classifications MeSH